The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

According to a Phase 3 trial published in The Lancet Diabetes & Endocrinology, a once-weekly combination of semaglutide and ...

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results media interaction.

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...